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MaBACKGROUND Although epinephrine is essential for successful return of spontaneous circulation (ROSC), the inﬂuence
of this drug on recovery during the post–cardiac arrest phase is debatable.
OBJECTIVES This study sought to investigate the relationship between pre-hospital use of epinephrine and functional
survival among patients with out-of-hospital cardiac arrest (OHCA) who achieved successful ROSC.
METHODS We included all patients with OHCA who achieved successful ROSC admitted to a cardiac arrest center from
January 2000 to August 2012. Use of epinephrine was coded as yes/no and by dose (none, 1 mg, 2 to 5 mg, >5 mg). A
favorable discharge outcome was coded using a Cerebral Performance Category 1 or 2. Analyses incorporated multi-
variable logistic regression, propensity scoring, and matching methods.
RESULTS Of the 1,556 eligible patients, 1,134 (73%) received epinephrine; 194 (17%) of these patients had a good
outcome versus 255 of 422 patients (63%) in the nontreated group (p < 0.001). This adverse association of epinephrine
was observed regardless of length of resuscitation or in-hospital interventions performed. Compared with patients who
did not receive epinephrine, the adjusted odds ratio of intact survival was 0.48 (95% conﬁdence interval [CI]: 0.27 to
0.84) for 1 mg of epinephrine, 0.30 (95% CI: 0.20 to 0.47) for 2 to 5 mg of epinephrine, and 0.23 (95% CI: 0.14 to 0.37)
for >5 mg of epinephrine. Delayed administration of epinephrine was associated with worse outcome.
CONCLUSIONS In this large cohort of patients who achieved ROSC, pre-hospital use of epinephrine was consistently
associated with a lower chance of survival, an association that showed a dose effect and persisted despite post-
resuscitation interventions. These ﬁndings suggest that additional studies to determine if and how epinephrine may
provide long-term functional survival beneﬁt are needed. (J Am Coll Cardiol 2014;64:2360–7) © 2014 by the American
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AB BR E V I A T I O N S
AND ACRONYM S
ACLS = advanced cardiac
life support
aOR = adjusted odds ratio
CI = conﬁdence interval
CPC = Cerebral Performance
Category
CPR = cardiopulmonary
resuscitation
OHCA = out-of-hospital
cardiac arrest
PCI = percutaneous coronary
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2361Although epinephrine can increase the likelihood
of achieving ROSC, the balance of the effects of
epinephrine on long-term survival remains uncertain.
A randomized study found no overall survival effect
of medication treatments that included epinephrine
(9). In a large observational study, epinephrine was
associated with a lower likelihood of long-term sur-
vival (10). In each of these studies, epinephrine was
associated with a greater likelihood of ROSC, but the
early potential beneﬁt did not translate into a greater
likelihood of long-term survival because outcomes
among the epinephrine-treated patients were worse
during the post-resuscitation phase.SEE PAGE 2368
intervention
ROSC = return of spontaneous
circulation
VF = ventricular ﬁbrillation
ventricular tachycardiaWesought to better understand the potential adverse
effects of epinephrine when used during the post-
resuscitation phase. We evaluated the relationship be-
tween use of epinephrine during resuscitation and
survival among a cohort of patients resuscitated from
out-of-hospital cardiac arrest (OHCA) and admitted
to the hospital with ROSC. We also evaluated whe-
ther evidence-based post-resuscitation interventions,
such as coronary reperfusion or hypothermia, may in-
ﬂuence this epinephrine-survival relationship.
METHODS
STUDY DESIGN, PATIENTS, AND SETTING. We per-
formed a cohort investigation of all patients who
experienced nontraumatic OHCA, achieved ROSC,
and were subsequently admitted to a large Parisian
cardiac arrest–receiving hospital from January 2000
to August 2012. The appropriate institutional review
board approved the study.
Management of OHCA involves mobile emergency
units and ﬁre departments that provide basic and ad-
vanced cardiac life support (ACLS). In suspected cases of
cardiac arrest, the closest emergency unit is dispatched
to the scene. Out-of-hospital resuscitation is performed
by an emergency team, which includes at least 1 emer-
gency physician trained according to international
guidelines (1). When used, epinephrine is administered
promptly at the beginning of ACLS or later if required.
Patients in whom the resuscitation process fails are not
transported to the hospital. Most patients who achieve
ROSC are brought to the cardiac arrest–receiving hospital
and admitted to the intensive care unit, where they are
treated according to standard resuscitative guidelines
including coronary angiography and mild therapeutic
hypothermia. Procedures of post–cardiac arrest care
have been described previously (11). Early coronary re-
perfusion and targeted temperature management are
the most important components of these procedures.DATA COLLECTION. The study hospital
maintains an ongoing registry of all patients
with OHCA who are admitted with ROSC. In-
formation is prospectively collected accord-
ing to Utstein recommendations (12). The
registry includes characteristics such as age,
sex, cardiovascular risk factors (hyperten-
sion, diabetes mellitus, and current smok-
ing), location of cardiac arrest, witnessed
status, bystander cardiopulmonary resusci-
tation (CPR), and initial cardiac rhythm as
recorded by the automated deﬁbrillator
(ventricular ﬁbrillation [VF]/ventricular tach-
ycardia [VT] or pulseless electrical activity/
asystole). The emergency medical service re-
cord is used to determine the time interval
between the emergency call and successful
ROSC as well as use of epinephrine, the
timing of the ﬁrst administration after cardiac arrest,
and the total dose. Hospital data during the post-
resuscitation phase include initial laboratory values,
such as blood lactate levels (mmol/l), and procedures,
such as therapeutic hypothermia, coronary angiog-
raphy, and percutaneous coronary intervention (PCI).
Post-resuscitation shock was deﬁned as the
occurrence or persistence of arterial hypotension
(mean arterial pressure <60 mm Hg or systolic blood
pressure <90 mm Hg) sustained for more than 6 h
after ROSC despite adequate ﬂuid resuscitation
and continuous vasopressor infusion (13). The de-
ﬁnitive etiology of the cardiac arrest was conﬁrmed at
hospital discharge, considering all available data
obtained during hospital stay. Acute coronary syn-
dromes and/or primary ventricular arrhythmia were
considered cardiac etiology. All other causes were
considered to be extracardiac causes. The primary
outcome was favorable neurological outcome at
discharge, deﬁned as a Cerebral Performance Cate-
gory (CPC) of 1 or 2.
STATISTICAL ANALYSIS. Categorical variables were
summarized with proportions and compared using
Pearson chi-square test or Fisher exact test. Contin-
uous variables were described with medians (and
quartiles) or means and compared using Student
t test or the nonparametric Wilcoxon test. Use of
epinephrine was classiﬁed both dichotomously (any
epinephrine vs. no epinephrine) and as a dose vari-
able divided into 4 categories: none, 1 mg, 2 to 5 mg,
and >5 mg.
We used multivariable logistic regression to eval-
uate the association between epinephrine and favor-
able neurological survival while adjusting for potential
confounders. We also set up a propensity model to
evaluate the relationship between epinephrine and
VT =
TABLE 1 Baseline Characteristics According to Use of Epinephrine
Treatment
With
Epinephrine
(n ¼ 1,134)
Treatment
Without
Epinephrine
(n ¼ 422) p Value
Age, yrs 60.3 (16) 58.3 (16) 0.02
Male 797 (70) 315 (75) 0.09
Hypertension 408 (40) 124 (32) 0.003
Diabetes mellitus 185 (18) 47 (12) 0.004
Smoking 380 (43) 163 (45) 0.35
Witnessed status 945 (87) 371 (92) 0.006
Bystander CPR 480 (43) 201 (49) 0.05
Public location 306 (27) 185 (44) <0.001
Initial shockable rhythm 554 (49) 291 (69) <0.001
Resuscitation length <20 min* 373 (38) 299 (80) <0.001
PCI 277 (24) 146 (35) <0.001
Hypothermia 765 (67) 318 (75) 0.003
Blood lactate >5.2 mmol/l1* 652 (63) 94 (23) <0.001
Post–cardiac arrest shock 750 (66) 191 (45) <0.001
Values are n (%). *Summarized with its median.
CPR¼ cardiopulmonary resuscitation; PCI¼ percutaneous coronary intervention.
FIGURE 1 Patient
Good Outcome
194/1134 (17%)
9
EPI+113
(73
Patient outcomes are
resuscitation. EPI ¼
TABLE 2 Multivariate Models Testing the Association Between
Use of Epinephrine and Good Neurological Outcome
Odds Ratio
95% Conﬁdence
Interval p Value
Crude association 0.14 0.10–0.17 <0.001
Standard logistic regression* 0.32 0.22–0.47 <0.001
Adjustment on PS† 0.35 0.24–0.50 <0.001
Cross-matching PS‡ 0.33 0.19–0.58 <0.001
Probability of PS‡
0.2–0.4 0.44 0.17–1.12 0.09
0.4–0.6 0.29 0.15–0.57 <0.001
0.6–0.8 0.30 0.15–0.62 0.001
0.8–1 0.31 0.16–0.60 0.001
IPTW PS‡ 0.18 0.13–0.27 <0.001
SMR PS‡ 0.18 0.13–0.26 <0.001
Year of inclusion
Before or in 2005‡ 0.38 0.21–0.70 0.002
After 2005‡ 0.29 0.18–0.47 <0.001
*Adjusted according to baseline characteristics (age, sex, hypertension, diabetes
mellitus, smoking, witnessed status, bystander CPR, length of resuscitation) and
hospital covariates (i.e., PCI, hypothermia, post–cardiac arrest shock, blood lactate
level). †Adjusted on propensity score and hospital covariates. ‡Adjusted on hos-
pital covariates.
Abbreviations as in Table 1. IPTW ¼ inverse probability of treatment weighting;
PS ¼ propensity score; SMR ¼ standard mortality ratio.
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2362outcome. The propensity of receiving epinephrine was
determined using pre-treatment characteristics. In an
effort to control for confounding, we also used
different methods (14,15) that included a logistic
regression model adjusted for the propensity score, 2
conditional logistic regression analyses after match-
ing on the propensity score in a 1:1 manner, stratiﬁca-
tion on quintiles of propensity score, and an inverse
probability of treatment weighted logistic regressionFlow
Bad Outcome
940/1134 (83%)
Good Outcome
255/422 (63%)
Bad Outcome
167/422 (37%)
1646 patients
01/2000-08/2012
0 Missing
1556 patients
4/1556
%)
EPI- 422/1556
(27%)
presented according to treatment with or without EPI during
epinephrine.model. Here, we performed an additional analysis
based on 1,000 bootstrap samples drawn with
replacement from the study population. At this step,
all models were adjusted on hospital potential con-
founders: PCI, therapeutic hypothermia, blood lactate
level, and occurrence of post–cardiac arrest shock.
We assessed for differences in the epinephrine-
outcome association among subgroups by including
an interaction (cross-product) term between the use
of epinephrine and the covariate of interest (initial
rhythm, intervals, post–cardiac arrest shock, etiology,
coronary angiography, and therapeutic hypothermia).
Because the period of study was more than a decade,
we performed an ancillary analysis on the period of
inclusion, especially before and after 2005, the year of
removed and new guidelines concerning pre-hospital
care (16). Finally, an ancillary analysis was performed
focusing on the intervals between cardiac arrest and
ACLS (ﬁrst administration of epinephrine).
All tests were 2-sided. A p value #0.05 was
considered statistically signiﬁcant. All analyses were
performed using Stata 11.2/SE software (College Sta-
tion, Texas).
RESULTS
During the study period, 1,646 patients achieved
ROSC and were admitted to the hospital. Of these, 90
(5.5%) had missing epinephrine status and were
excluded from the analysis.
FIGURE 2 Neurological Outcome in Treated and Nontreated Patients
According to Subgroups
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The adverse association between use of EPI and survival was evident according to (A)
initial rhythm, (B) length of resuscitation, (C) performance of hypothermia, and (D) per-
formance of PCI. CI ¼ conﬁdence interval; EPI ¼ epinephrine; PCI ¼ percutaneous coronary
intervention.
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2363On average, the cohort was 60  16 years of age,
71% (1,112 of 1,556) were male, and 54% (845 of 1,556)
presented with an initial shockable rhythm. Coronary
angiography was performed in 63% (961 of 1,534)
and PCI in 44% (423 of 961). Approximately 70%
of patients (1,083 of 1,556) underwent therapeutic
hypothermia.
Nearly three-fourths of patients received epi-
nephrine as part of OHCA resuscitation (Table 1). Pa-
tient characteristics differed according to epinephrine
status. Those receiving epinephrine had less favor-
able prognostic characteristics; for example, they
were older (p ¼ 0.02), less likely to have a witnessed
event (p ¼ 0.006), were less likely to present with a
shockable rhythm (p < 0.001), and had a longer
duration of resuscitation (p < 0.001).
Of the 1,556 patients included in this study, 482
(31%) had overall survival to hospital discharge and
449 (29%) had survival with good neurological
outcome. Survival with good neurological outcome
(CPC 1 or 2) was less likely among those who received
epinephrine compared with those who did not receive
epinephrine (194 of 1,134 [17%] vs. 255 of 422 [60%],
respectively; p < 0.001) (Figure 1).
After adjusting for the different confounders, use
of epinephrine was negatively associated with
favorable neurological outcome (adjusted odds ratio
[aOR]: 0.32; 95% conﬁdence interval [CI]: 0.22 to
0.47), even after adjusting for hospital interventions.
Furthermore, the hospital predictive factors for good
outcome were PCI (aOR: 0.88; 95% CI: 1.34 to 2.65),
blood lactate level >5.2 mmol/l1 (aOR: 0.41; 95% CI:
0.29 to 0.58), and the occurrence of post–cardiac ar-
rest shock (aOR: 0.66; 95% CI: 0.48 to 0.92). Thera-
peutic hypothermia was signiﬁcantly associated with
good outcome only after restricting analyses to pa-
tients with VF/VT (aOR: 1.69; 95% CI: 1.04 to 2.75)
(Online Table 1).
The logistic model used to estimate the pro-
pensity score for receiving epinephrine using all
available covariates yielded a C statistic of 0.80.
From the propensity score, 228 pairs of treated and
nontreated patients were matched, and the inter-
vention group was similar with regard to covariates
compared with the nontreated group (Online Tables
2 and 3). In this matched analysis, 68 of 228 pa-
tients (30%) in the treated group had a good
outcome whereas 138 of 228 patients (61%) in the
nontreated group were discharged with CPC 1 or 2
(p < 0.001). The negative association between the
use of epinephrine and outcome persisted after
stratifying on quintiles of propensity score and after
use of weighted models (Table 2). Similarly, use of
epinephrine was associated with lower odds ofsurvival before and after the change in guidelines
in 2005.
When focusing on the time intervals between
collapse and ﬁrst use of epinephrine, we observed
that ACLS delays were similar in patients treated
with or without epinephrine (13.6  10.1 min vs.
13.6  9.8 min; p ¼ 0.98) and that the delay for ﬁrst
administration of treatment, if appropriate, was
16.1  10.6 min after collapse. Although longer in-
tervals for ACLS were associated with worse
outcome, the inﬂuence of epinephrine remained
adverse whatever the delay (Online Figure 1) (p for
interaction ¼ NS).
Moreover, the delay between cardiac arrest and
ﬁrst dose of epinephrine was linearly related to a bad
outcome. Patients in whom epinephrine was given
within the ﬁrst 9 min after cardiac arrest had a better
FIGURE 3 Association Between Outcome and Early Dose of EPI and According
to the Initial Rhythm
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The odds ratios were adjusted according to baseline characteristics (age, sex, hypertension,
diabetes mellitus, smoking, witnessed status, bystander cardiopulmonary resuscitation,
length of resuscitation), and hospital covariates (PCI, hypothermia, post–cardiac arrest
shock, blood lactate level). Abbreviations as in Figures 1 and 2.
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2364outcome (aOR: 0.54; 95% CI: 0.32 to 0.91) compared
with those who received treatment between 10 and 15
min (aOR: 0.33; 95% CI: 0.20 to 0.56), between 16 and
22 min (aOR: 0.23; 95% CI: 0.12 to 0.43), and >22 min
after cardiac arrest (aOR: 0.17; 95% CI: 0.09 to 0.34)
(Online Figure 2).
The adverse association between use of epineph-
rine and survival was evident across subgroups
deﬁned by initial rhythm, length of resuscitation and
post-resuscitation care (including hypothermia and
PCI status), and the presence or absence of post-
resuscitation shock (Figure 2). For example, the aOR
for use of epinephrine and neurologically intact sur-
vival was 0.31 (95% CI: 0.20 to 0.48) among those who
underwent therapeutic hypothermia and 0.37 (95%
CI: 0.15 to 0.92) among those who did not undergo
therapeutic hypothermia. In addition, we observed a
stepwise dose association with decreasing odds of
survival with CPC 1 or 2 associated with an increasing
dose of epinephrine. Overall, compared with patients
who did not receive epinephrine during resuscitation,
the aOR of intact survival varied by dose of epi-
nephrine: 0.48 (95% CI: 0.27 to 0.84) for 1 mg, 0.30
(95% CI: 0.20 to 0.47) for 2 to 5 mg, and 0.23 (95% CI:
0.14 to 0.37) for >5 mg (Figure 3). A similar dose
relationship was observed across the a priori sub-
groups (Online Figures 3A to 3C).DISCUSSION
In this large cohort, use of epinephrine during
resuscitation of OHCA was associated with a worse
neurological outcome during the post-resuscitation
period after adjustment for confounding factors.
This relationship was robust to a variety of different
methodological approaches designed to limit con-
founding. The adverse association of epinephrine was
not modiﬁed by post-resuscitation interventions such
as PCI or therapeutic hypothermia. Importantly, the
timing of ﬁrst administration and epinephrine dose
response became critical in terms of the potential
beneﬁt of this drug (Central Illustration).
Even if it is impossible to circumvent in many cases,
use of epinephrine was independently associated with
a decreased likelihood of neurologically intact survival
among patients who successfully achieved ROSC.
Although epinephrine is known to increase ROSC after
arrest (17,18), its effects during the post-resuscitation
phase on later outcome are not clear, with potential
for relative harm (9,10,19). The beneﬁt of this drug
when used during the resuscitation period relies on
the implied vasostress, which in turn may also
promote secondary detrimental effects during the
post–cardiac arrest phase, combining myocardial
dysfunction, ischemia-reperfusion, and post-anoxic
injury (20). Several animal studies support these mec-
hanisms (6,8,21,22). Furthermore, use of epinephrine
was associated with post-resuscitation shock and
increased blood lactate levels. Previous clinical studies
(both randomized and observational) suggested that
epinephrine might worsen survival at hospital dis-
charge and later outcome (9,10,19,23–25). These
studies converged, suggesting a potential risk of use
of epinephrine, especially in VF/VT groups; however,
the investigations were not statistically deﬁnitive or
did not focus on the role of post-resuscitation care.
One hypothesis is that the potential adverse post-
resuscitation effects of epinephrine could be attenu-
ated by in-hospital interventions such as PCI or
hypothermia; these relationships have not been fully
investigated (23). By focusing on patients with suc-
cessful ROSC and by integrating post–cardiac arrest
care into our analysis, we assessed the speciﬁc inﬂu-
ence of the drug on the post–cardiac arrest period and
conﬁrmed that this period is the time frame during
which epinephrine may reveal adverse effects. Im-
portantly, we observed a negative association of
epinephrine across all subgroups, even in patients
treated with hospital interventions such as PCI and
hypothermia.
It could be contended that epinephrine should be
considered a surrogate marker of severity rather than
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Administration of epinephrine during cardiac arrest is associated with worse neurological
outcomes in resuscitated patients. This effect is consistent in all subgroups of patients and
increased with the cumulated dosage and delay of the ﬁrst administration (association
between epinephrine and worse neurological outcome at discharge, expressed as odds
ratios with 95% conﬁdence intervals, adjusted on confounders).
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2365an independent predictive factor, complicating the
current debate on the beneﬁt of this agent (26). How-
ever, this relationship has been already described
when looking at observational data and the few ran-
domized studies that were recently performed (5,27).
We made multiple methodological efforts (using pro-
pensity score, cross-matching, and different sensi-
tivity analysis) to discriminate the speciﬁc role of
the intervention. The results were robust regardless
of the methodological approach. To our knowledge,
this is the ﬁrst study depicting such a linear relation-
ship between the dose and outcome, which is consis-
tent with an increasing effect of the ascendant dose
of the drug. Some studies have previously shown
that repeated and increased doses of epinephrine
could worsen the chances of survival (28,29).
Before incriminating the drug itself, our ﬁndings
probably should provoke further discussion on the
most appropriate scheme of treatment and its inter-
action regarding the resuscitation phases. Our sensi-
tivity analyses showed that the role of epinephrine
did not change according to ACLS delay or length of
resuscitation but was clearly dependent on the timing
of ﬁrst administration. These last ﬁndings are con-
sistent with other studies, emphasizing the potential
beneﬁt of an early dose of epinephrine (30–32).
Moreover, these observations concur with what
Weisfeldt and Becker (33) previously described as the
3 phases of resuscitation in VF arrest: “the electrical
phase” within the ﬁrst few minutes after arrest, in
which epinephrine should not be required; “the cir-
culatory phase,” during which time chest compres-
sions and epinephrine could help reperfusion; and
ﬁnally “the metabolic phase,” when the drug may be
detrimental in regard to the peripheral ischemia
release of massively cytotoxic proteins. As supported
by our results, it is highly probable that patients
receiving late or repeated doses of epinephrine have
little or low chance of survival. Currently, no existing
alternative can bring these patients back from near-
death except mechanical circulatory assistance in
very select cases. Altogether, the scheme and timing
of administration may be crucial to provide the
appropriate effect of epinephrine.
This study highlights the need to assess the quality
of resuscitation, such as the quality of CPR and ACLS
response (34–36), to improve clinical practice (37,38).
We may be able to better understand the role of
epinephrine with careful investigation of its timing
and dose in the context of intermediate outcomes
such as the electrocardiographic waveform and
rhythm transition, end-tidal carbon dioxide, and
brain perfusion (31,39). Finally, our results highlight
the need for additional studies with differentschemes of treatment, such as the combination of
epinephrine with other drugs such as vasopressin or
beta-blockers (40).
STUDY LIMITATIONS. This study is limited by its
observational design; consequently, it precludes any
causal relationship between use of epinephrine and
outcome. However, we used a variety of analytical
approaches to rigorously address confounding. De-
spite our efforts, some potential confounders may not
have been included; for instance, we do not have
reliable time points for establishment of an intrave-
nous or intraosseous line. Our ﬁndings are drawn
from a single center and may not be generalizable to
all communities.
Guidelines have supported the use of additional
outcome endpoints such as 90-day survival in
evaluating treatment effects. However, using the
CPC score at discharge appears to be a good indi-
cator of long-term survival (41). These limitations
should be considered in the context of the strengths
of this study: a large cohort with detailed
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
During resuscitation of patients with out-of-hospital
cardiac arrest, administration of epinephrine may
enhance the likelihood of return of spontaneous cir-
culation but is associated with worse neurological
outcomes and the impact on long-term survival is
uncertain.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to assess the impact of other treatment
strategies for patients with out-of-hospital cardiac
arrest, such as combinations of epinephrine and
other drugs, on time to return of spontaneous
circulation, neurological outcomes, and long-term
survival.
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2366information ascertained using a standard approach
to data abstraction regarding care and outcome.
CONCLUSIONS
In this large cohort of patients who achieved ROSC
after OHCA, we observed an adverse association be-
tween epinephrine and neurologically intact survival
despite rigorous efforts to address confounding; this
relationship was not modiﬁed by speciﬁc post-
resuscitation care such as hypothermia or PCI. As a
result, these ﬁndings suggest the need for additional
investigations to determine if and how epinephrine
may provide long-term functional survival beneﬁt.
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